革新抗纤溶治疗:针对全髋关节置换术后纤溶反应差异患者的个体化策略
该随机对照试验前瞻性纳入204例因终末期髋病行全髋关节置换术的患者,随机分为对照组和抗纤溶组,依据术后第1天LY30水平分为纤溶关闭(FSD)与非纤溶关闭(NFSD)亚组。结果显示FSD患者较NFSD患者失血量更少且不能从经验性抗纤溶治疗中获益,提示应基于纤溶表型制定个体化抗纤溶策略。
要点
- 全髋关节置换术后患者存在以LY30区分的不同纤溶表型。
- FSD患者较NFSD患者术后失血量更少。
- FSD患者不能从经验性抗纤溶治疗中获益。
核心结论
- 全髋关节置换术后患者表现出不同的纤溶表型,可通过LY30识别。
- 与NFSD患者相比,FSD患者失血量显著更少,且不能从经验性抗纤溶治疗中获益,强调个体化抗纤溶治疗的必要性。
研究设计与样本
- 随机对照试验,前瞻性招募204例因终末期髋病行全髋关节置换术的患者,随机分为对照组和抗纤溶组。
- 根据术后第1天LY30水平将患者分为纤溶关闭(FSD)和非纤溶关闭(NFSD)亚组。
- 主要结局为术后隐藏失血量(HBL)和血红蛋白下降值(ΔHb),同时记录并比较关键凝血指标、静脉血栓栓塞发生率及其他并发症。
主要发现
- 在对照组中,NFSD患者术后第3天的HBL和ΔHb显著高于FSD患者,术后第1天无差异。
- 在抗纤溶组中,NFSD与FSD患者的HBL和ΔHb水平保持一致。
- 基于表型的分析显示,抗纤溶治疗显著降低NFSD患者术后第3天的HBL和ΔHb,术后第1天无变化。
- 抗纤溶治疗未能降低FSD患者术后第1天和术后第3天的HBL和ΔHb。
- 两个分析阶段中,凝血指标、静脉血栓栓塞或其他并发症均无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While empirical antifibrinolysis immediately postsurgery effectively reduces postoperative hidden blood loss (HBL), the emerging concept of fibrinolytic phenotypes may challenge this routine practice. This randomized controlled trial investigated the efficacy of using the fibrinolytic marker LY30 to distinguish divergent phenotypes following total hip arthroplasty (THA), thereby enabling personalized antifibrinolysis strategies. METHODS: There were 204 patients undergoing THA for end-stage hip diseases prospectively recruited and randomly assigned to control and antifibrinolysis groups. Based on the LY30 levels on postoperative day one (POD one), patients were further classified into four subgroups: fibrinolytic shutdown (FSD) and nonfibrinolytic shutdown (NFSD). Primary outcomes assessed were HBL and hemoglobin drop (ΔHb). Key coagulation metrics, incidence of venous thromboembolism, and additional complications were also recorded and compared. RESULTS: There were two rounds of statistical analyses conducted based on different interventions and fibrinolytic phenotypes, respectively. The first intervention-specific analysis revealed that in the control group, NFSD patients suffered significantly higher HBL and ΔHb on POD3 compared to FSD patients, with no differences observed on POD1. However, in the antifibrinolysis group, the HBL and ΔHb levels remained consistent between NFSD and FSD patients. The second phenotype-based analysis indicated that the antifibrinolytic therapy significantly reduced the HBL and ΔHb in NFSD patients on POD three, with no changes on POD one. In contrast, the same treatment failed to reduce the HBL and ΔHb in FSD patients, neither on POD one nor on POD three. Throughout both analytical stages, there were no statistically significant variations in coagulation metrics, venous thromboembolism, or other complications. CONCLUSIONS: The THA patients exhibited diverse fibrinolytic phenotypes post-surgery, identifiable by LY30. Compared to NFSD patients, FSD patients experienced significantly less blood loss and derived no benefits from the empirical antifibrinolytic therapy, emphasizing the necessity of tailoring antifibrinolysis treatment.
引用
- Luo X, Liu J, Zhang T, et al. Revolutionizing Antifibrinolytic Therapy: Personalized Strategies for Total Hip Arthroplasty Patients Who Have Divergent Fibrinolytic Responses. J Arthroplasty. 2025. PMID: 40846122. doi:10.1016/j.arth.2025.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。